A federal government website managed by the U.S. Department of Health & Human Services
200 Independence Avenue, S.W. - Washington, D.C. 20201
Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Influenza Prevention and Control Recommendations
This year's recommendations for the 2011-12 influenza season are issued in a shortened format because there are relatively few changes from the 2010-11 recommendations.
The 2010-11 influenza vaccine recommendations and related updates should continue to be referenced for other information on influenza vaccines not contained in the 2011-12 recommendations.
New Information for the 2011-12 Influenza Season
- Vaccine virus strains for the 2011-12 influenza season
- Vaccination schedule for children aged 6 months through 8 years
- Considerations and recommendations regarding vaccination of persons reporting allergy to eggs
- A new formulation of trivalent inactivated vaccine that is given intradermally (into the skin) for adults aged 18 through 64 years
- TABLE. Influenza vaccine information, by age group --- United States, 2011--12 influenza season
Current References for the 2011-12 Season
The following recommendations were released for the 2010-11 season but should be considered current references for the 2011-12 season.
- Recommendations of the Advisory Committee on Immunization Practices (ACIP) Regarding Use of CSL Seasonal Influenza Vaccine (Afluria)
- Afluria vaccine should not be administered to children aged 6 months through 8 years.
- Excerpts of Prevention & Control of Influenza with Vaccines - 2010-11 Recommendations of the Advisory Committee on Immunization Practices
Background
Vaccination
- Summary of Influenza Vaccination Recommendations
- Vaccine Composition
- Major Differences Between TIV and LAIV
- Recommendations for Using TIV and LAIV
- Dosage, Administration, and Storage
- Concurrent Administration of Influenza Vaccine with Other Vaccines
- Influenza Vaccines and Use of Influenza Antiviral Medications
- Shedding, Transmissibility and Stability of LAIV Viruses
- Adverse Events After Receipt of LAIV
- Adverse Events After Receipt of TIV
- Timing of Vaccination
- Influenza Vaccine Supply Considerations
- Evaluating Vaccine Studies
NOTE: For 2011-12 Influenza Prevention and Control Recommendations see "Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011," MMWR 2011 Aug 26; 60(33):1128-1132.
For 2010-11 Influenza Prevention and Control Recommendations see "Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010," MMWR 2010 Aug 6; 59(RR08):1-62.
Last syndicated: March 19, 2012 10:34 PM EDT
This content is brought to you by the Centers for Disease Control and Prevention (CDC)
Get Email Updates
Flu.gov RSS
Podcasts